Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907273 | 0.70 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL29360677 | 0.70 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL24534338 | 0.70 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL29419014 | 0.70 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2E1 | |
| SCHEMBL30473120 | 0.70 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2E1 | |
| SCHEMBL120088 | 0.70 | CYP2A6 (1.00) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2E1 | |
| SCHEMBL255921 | 0.69 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2E1 | |
| SCHEMBL30437385 | 0.69 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2E1 | |
| SCHEMBL7611926 | 0.69 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP2E1 | |
| SCHEMBL8935802 | 0.68 | CYP2A6 (0.69) | CYP2A6ALDH1A1CYP3A4CYP1A2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009137380-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-12 | — | — | WO | claimed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | claimed |
| US-20110237595-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | BASF SE (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | BASF SE (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2251324-A1 | HETEROARYL-ALKYLCARBAMATE COMPOUNDS AND THEIR USE AS INHIBITORS OF THE FAAH ENZYME | Sanofi-Aventis (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-20100069405-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| US-7645757-B2 | Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-01-12 | — | — | US | disclosed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
| EP-1720829-B1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-10-14 | — | — | EP | disclosed |
| US-20070021426-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | TPMT, NQO2, TST | CYP2A6 637/4885ALDH1A1 1071/4885CYP3A4 484/4885 |
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | STS, NAPA, NAAA | CYP2A6 278/4885ALDH1A1 2768/4885CYP3A4 1277/4885 |
| US-20110237595-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR1 | CYP2A6 220/4885ALDH1A1 802/4885CYP3A4 536/4885 |
| US-20100069405-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR1 | CYP2A6 220/4885ALDH1A1 802/4885CYP3A4 536/4885 |
| US-20070021426-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CYP2A6 220/4885ALDH1A1 1002/4885CYP3A4 834/4885 |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | CYP2A6 1607/4885ALDH1A1 1070/4885CYP3A4 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.